Overview

Phase 3 Efficacy Study in the Evaluation of the Safety and Efficacy of LNZ101 for the Treatment of Presbyopia

Status:
Not yet recruiting
Trial end date:
2024-04-01
Target enrollment:
Participant gender:
Summary
Phase 3 Efficacy Study to evaluate the Safety and Efficacy of LNZ101 for the Treatment of Presbyopia
Phase:
Phase 3
Details
Lead Sponsor:
LENZ Therapeutics, Inc
Collaborator:
ORA, Inc.
Treatments:
Aceclidine
Brimonidine Tartrate
Ophthalmic Solutions